Baird said Micron's valuation remains attractive following Q4 results. The firm believes a recovery will occur in 2H13 driven by a lack of new capacity and its fundamentals will be strengthened by its Elpida acquisition. Shares are Outperform rated with a $10 price target.
The U.S. Federal Reserve's explicit signal it will stop pumping money into the world economy and data showing China's …